RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Nuance Biotech of Shanghai in-licensed China rights to a non-opioid treatment for long-lasting pain following surgery from US-based Pacira Pharma in a $58 million agreement. Nuance will pay $3 million upfront and the rest in milestones, plus royalties. Nuance plans to file a Clinical Trial Application in China later this year. Pacira describes Exparel® (bupivacaine liposome injectable suspension) as an anesthesia deposited at the site during surgery or administered as an interscalene brachial plexus nerve block.
Source: China Biotoday
